IP Library Granted Patent US 12,187,749
Granted Patent B2
US 12,187,749 · App. 18/162,205 · Granted Jan 7, 2025

Application of dipyrrinato-iridium complexes in anti-tumor and anti-bacterial therapy

Inventors: Benjamin Florian Hohlfeld (Berlin, DE); Arno Wiehe (Berlin, DE); Burkhard Gitter (Jena, DE); Dorika Steen (Jena, DE); Gerhard Wieland (Jena, DE); Volker Albrecht (Nuthetal, DE)
Assignee: BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG
C07F15/0033A61K41/0057A61K47/549A61P31/04A61P35/00C07F17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,187,749
App. No.
18/162,205
Granted
Jan 7, 2025
Kind
B2
Abstract

Biologically active compounds and their methods of preparation are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, otorhinolaryngology disorders, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Embodiments also include methods to synthesize iridium(III) complex structures incorporating a substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetratfluorophenyldipyrrin) unit or a substituted 3-nitrophenyl-dipyrromethene (3-nitrophenyl-dipyrrin) unit. Amphiphilic compounds with increased anti-tumour and anti-bacterial efficacy are also provided. Specifically, this is achieved by substitution with bromine atoms and sugar moieties.

Claims (16)

1. An iridium compound of formula 1, 2, 3 or 4:

Wherein:

X is at least one of O, NH or S;

R 1 is at least one of a carbohydrate moiety, a short alkyl chain with 3 to 6 carbon atoms, propargyl, HO—CH 2 —CH 2 —, CH(CH 2 OH) 2 , CH 2 —CH(OH)—CH 2 OH, or CH(OH)—CH(OH)—CH 3 ; and

R 2 is at least one of hydrogen or a methyl group.

2. The compound of claim 1 for use in tumor therapy.

3. The compound of claim 1 for use in photodynamic therapy.

4. The compound of claim 1 for use in the therapy of at least one of tumors, dermatological disorders, viral infections, bacterial infections, otorhinolaryngology disorders, ophthalmological disorders or urological disorders.

5. The compound of claim 1 for use in the photodynamic therapy of at least one of tumors, dermatological disorders, viral infections, bacterial infections, otorhinolaryngology disorders, ophthalmological disorders or urological disorders.

6. A compound of claim 1 as a component in the preparation of a pharmaceutical composition for tumor therapy or photodynamic tumor therapy.

7. The compound of claim 1 for use in the therapy or photodynamic therapy of arthritis and inflammatory diseases.

8. The compound of claim 1 for use in the diagnosis of arthritis and inflammatory diseases or in the diagnosis of tumors.

9. The compound of claim 1 when loaded onto a surface of a medical device.

10. A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient.

11. The pharmaceutical composition of claim 10 , wherein the compound is conjugated to a targeting agent.

12. The pharmaceutical composition of claim 11 , wherein the targeting agent is a peptide.

Assignments (2)
CHANGE OF NAME Recorded Aug 23, 2024
From: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG
Reel/Frame 068381/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2024
From: HOHLFELD, BENJAMIN FLORIAN; WIEHE, ARNO; GITTER, BURKHARD; STEEN, DORIKA; WIELAND, GERHARD; ALBRECHT, VOLKER
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 066183/0871 →
Continuity (3)
Continuation PCTEP2021071590 · Aug 2, 2021
Provisional Application 63060572 · Aug 3, 2020
Related Publication 20230242559A1 · Aug 3, 2023
References Cited (2)
Hohlfeld et al. Dipyrrinato-Iridium(III) complexes for application in photodynamic therapy and antimicrobial photodynamic inactivation, (Chemistry-A European Journal, 27, 6440-6459). (Year: 2021). [cited by examiner]
Takaki et al. Controlling the Electronic Structures and Excited-State Characteristics of dipyrrinatoiridium(III) complexes by an arylborane or an arylamino unit (Inorg. Chem. 58, 14542-14550). (Year: 2019). [cited by examiner]